Jubilant Pharmova – formerly Jubilant Life Sciences – plans to separate and move the active pharmaceutical ingredient business currently in the hands of its generic pharmaceuticals subsidiary, taking eventual control of the business itself.

Oncology diagnoses and therefore revenues are returning as we emerge from the pandemic, but the recovery also brings the challenges of reduced diagnostic and eventually vaccine revenues.

US FDA’s first decision on biosimilars interchangeability might have less meaning for two insulin products, but payer and prescriber responses to interchangeable biosimilars for adalimumab, which are further out on the horizon, may be more instructive regarding the importance of interchangeability status.

The European Medicines Agency is meeting this week to consider applications to broaden the use of approved drugs to include new indications in the EU.